– Whether patients with hypercholesterolemia in primary and 2nd-ary prevention are at the higher risk of severe course of the Covid-19 disease and why, and how to optimally prevent this and reduce the risk of COVID-19 complications,

– How to optimally treat patients with ACS? What we should do in order to achieve the goal of the therapy <70 mg/dL for high risk, <55 form very high risk and <40 for extremely high risk?

– Whether we should start with fixed combination/polypills with statins and ezetimibe and add PCSK9 inhibitors as quickly as possible (during hospitalization)? What might be the role of the well-prepared discharge letter? 

– What about the safety of the lipid-lowering therapy with Covid-19 drugs, including antiviral drugs (remdesivir), antiretroviral drugs (lopinavir/ritonavir), macrolides (mainly azithromycin), anti-malaria (chloroquine and hydroxychloroquine) and anti-rheumatoid (tocilizumab),

– What is the current status of the reimbursement of PCSK9 inhibitors for ACS in different CEE countries? When we might expect we will be able to treat our patients effectively?